Digestive and Metabolic Diseases

Non-Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease has become the most common liver disorder globally, closely associated with obesity, insulin resistance, and type 2 diabetes. NAFLD encompasses a spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma. The disease is largely asymptomatic in early stages, making awareness and screening crucial.

This session will focus on the mechanisms driving NAFLD, its diagnostic criteria, and therapeutic strategies. Lifestyle interventions, including diet and physical activity, remain the cornerstone of treatment. Additionally, pharmacologic approaches under development, such as insulin sensitizers, lipid-lowering agents, and anti-inflammatory drugs, offer promise. The session will also highlight the need for global awareness and policy changes to tackle this silent epidemic.

Key Topics:

• Epidemiology and pathogenesis of NAFLD

• Diagnostic imaging and liver biopsy

• Role of obesity and insulin resistance

• Progression to NASH and cirrhosis

• Lifestyle and dietary interventions

• Emerging pharmacologic therapies

• Cardiovascular risks and comorbidities

• NAFLD in pediatric populations

• Fibrosis scoring and monitoring

• Public health implications and policies